中国分化型甲状腺癌患者全甲状腺切除与放射性碘残留消融后结局的动态风险估计
该回顾性研究纳入台湾一家三级区域医院356例分化型甲状腺癌(WDTC)患者,术后及首次131I消融后按AJCC分期和ATA风险分层,并在首次消融后6–24个月按初始治疗反应再分类(RTR)系统评估。三种系统均可预测结构性疾病持续(SPD)随分期增加而升高、无疾病证据(NED)随分期增加而降低的趋势;RTR可显著细化ATA风险估计,尤其在高危组。
要点
- ATA高危组中29.2%在随访期间出现SPD/RD。
- RTR将治疗反应极佳者的SPD/RD可能性降至3.7%,将结构不完全反应者升至78.6%。
- 术后早期因素中,仅首次131I消融时的Tg水平可预测长期持续/复发。
核心结论
- 研究结果高度支持在中国WDTC患者随访中纳入RTR系统以修正初始风险估计。
研究设计与样本
- 回顾性研究,纳入台湾一家三级区域医院356例WDTC患者,平均年龄41.5±12.7岁,术后及131I残留消融后随访至少五年(12.3±5.0年)。
- 术后及首次131I残留消融后按AJCC分期(I–IV期)和ATA风险分层(低、中、高危)进行风险分层,并在首次131I消融后6–24个月按RTR系统(极佳、不确定、生化不完全、结构不完全反应)再分类。
主要发现
- 末次随访时,78.4%(n=279)患者为NED,9.3%(n=33)为BPD,10.1%(n=36)为SPD,2.2%(n=8)出现RD。
- 三种系统均可预测随着疾病分期进展SPD呈升高趋势、NED呈降低趋势。
- ATA风险估计可被RTR系统显著细化,尤其ATA高危组中29.2%在随访期间出现SPD/RD。
- RTR系统将治疗反应极佳者出现SPD/RD的可能性降至3.7%,将结构不完全反应者升至78.6%。
- 术后早期因素中,仅首次131I消融时的Tg水平可预测长期持续/复发。
临床怎么用
- 作者认为,在中国WDTC患者随访中应纳入RTR系统以修正初始风险估计。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was conducted to compare the staging systems for the prediction of long-term disease status in patients with well-differentiated thyroid carcinoma (WDTC), and to find out the earliest postoperative period predictor of long-term persistence/recurrence of disease. METHODS: Patients with WDTC (n = 356; Mage = 41.5 ± 12.7 years) followed for at least five years (12.3 ± 5.0 years) after thyroidectomy and 131I remnant ablation at a tertiary regional hospital in Taiwan were retrospectively studied. Each patient was risk stratified using the American Joint Cancer Committee (stage I-IV) and American Thyroid Association (low, intermediate, and high risk) staging systems after operation and first 131I remnant ablation and using response to initial therapy reclassification (RTR; excellent, indeterminate, biochemical incomplete, and structural incomplete response) system, which is determined 6-24 months after the first 131I ablation. The clinical outcome was defined as no evidence of disease (NED; suppressed thyroglobulin [Tg] <0.5 ng/mL, stimulated Tg <1 ng/mL, and no structural detectable disease), biochemical persistent disease (BPD; suppressed Tg ≥0.5 ng/mL or stimulated Tg ≥1 ng/mL in the absence of structural disease), structural persistent disease (SPD; locoregional or distant metastases with any Tg level), or recurrent disease (RD; biochemical or structural disease identified after a period of NED). RESULTS: At the time of final follow-up, 78.4% (n = 279) of the patients had NED, 9.3% (n = 33) had BPD, 10.1% (n = 36) had SPD, and 2.2% (n = 8) developed RD. All three systems could predict the increasing trend of SPD and the decreasing trend of NED with advancing stage of disease. However, the ATA risk estimates could be significantly refined by the RTR system, especially for the ATA high-risk group, in which 29.2% developed SPD/RD during follow-up. The RTR system reduced the likelihood of finding SPD/RD to 3.7% in those demonstrating an excellent response to therapy, and increased the likelihood to 78.6% in those demonstrating a structural incomplete response. Among the earliest postoperative factors, only the Tg level at the first 131I ablation could predict long-term persistence/recurrence. CONCLUSIONS: The results highly support incorporating the RTR system to modify the initial risk estimate during follow-up among Chinese patients with WDTC.
引用
- Shen FC, Hsieh CJ, Huang IC, et al. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation. Thyroid. 2017. PMID: 28007013. doi:10.1089/thy.2016.0479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。